Johnson & Johnson Reports Q2 2021 Results

- July 21st, 2021

Johnson & Johnson today announced results for second-quarter. “Our second-quarter results showcase Johnson & Johnson’s diversified portfolio, driven by strong sales and earnings growth across our Medical Device, Consumer Health and Pharmaceutical businesses,” said Alex Gorsky Chairman and Chief Executive Officer. “I’m so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to …

– Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter. “Our second-quarter results showcase Johnson & Johnson’s diversified portfolio, driven by strong sales and earnings growth across our Medical Device, Consumer Health and Pharmaceutical businesses,” said Alex Gorsky Chairman and Chief Executive Officer. “I’m so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to patients and consumers around the world, in addition to advancing our pipeline with new product launches and regulatory submissions. These accomplishments exemplify our commitment to advancing transformational innovations that improve the health of people and communities everywhere while continuing to deliver long-term value to all of our stakeholders.”

OVERALL FINANCIAL RESULTS

Q2

($ in Millions, except EPS)

2021

2020

%  Change

Reported Sales

$       23,312

$       18,336

27.1%

Net Earnings

6,278

3,626

73.1

EPS (diluted)

$           2.35

$           1.36

72.8%

Q2

Non-GAAP* ($ in Millions, except EPS)

2021

2020

%  Change

Operational Sales 1,2

23.0%

Adjusted Operational Sales 1,3

23.8

Adjusted Net Earnings 1,4

6,625

4,446

49.0

Adjusted EPS (diluted) 1,4

$           2.48

$           1.67

48.5%

1

Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

2

Excludes the impact of translational currency

3

Excludes the net impact of acquisitions and divestitures and translational currency

4

Excludes intangible amortization expense and special items

REGIONAL SALES RESULTS

Q2

%  Change

($ in Millions)

2021

2020

Reported

Operational 1,2

Currency

Adjusted
Operational 1,3

U.S.

$      11,919

$        9,539

24.9%

24.9

25.1

International

11,393

8,797

29.5

20.9

8.6

22.4

Worldwide

$      23,312

$      18,336

27.1%

23.0

4.1

23.8

1

Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

2

Excludes the impact of translational currency

3

Excludes the net impact of acquisitions and divestitures and translational currency

Note: values may have been rounded

SEGMENT SALES RESULTS

Q2

%  Change

($ in Millions)

2021

2020

Reported

Operational 1,2

Currency

Adjusted
Operational 1,3

Consumer Health

$        3,735

$        3,296

13.3%

9.2

4.1

10.0

Pharmaceutical

12,599

10,752

17.2

13.6

3.6

14.1

Medical Devices

6,978

4,288

62.7

57.2

5.5

58.7

Worldwide

$      23,312

$      18,336

27.1%

23.0

4.1

23.8

1

Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

2

Excludes the impact of translational currency

3

Excludes the net impact of acquisitions and divestitures and translational currency

Note: values may have been rounded

Second Quarter 2021 SEGMENT COMMENTARY:

Consumer Health
Consumer Health worldwide operational sales, excluding the net impact of acquisitions and divestitures, increased 10.0%* inclusive of the market recovery from COVID-19 impacts, primarily in skin health/beauty.  Sales growth was driven by skin health/beauty products including NEUTROGENA, AVEENO, and OGX; over-the-counter products including ZYRTEC in upper respiratory products, international analgesics, and digestive health products; and BAND-AID ® Brand Adhesive Bandages in wound care products.

Pharmaceutical
Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 14.1%* driven by STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, DARZALEX (daratumumab), for the treatment of multiple myeloma, TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer, and INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults. This growth was partially offset by biosimilar and generic competition, with declines primarily in REMICADE (infliximab), a biologic approved for the treatment of a number of immune-mediated inflammatory diseases.

Medical Devices
Medical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 58.7%*, primarily driven by the benefit of market recovery from COVID-19 impacts and the associated deferral of medical procedures in the prior year across all of our businesses including Surgery, Orthopaedics, Vision and Interventional Solutions.

NOTABLE NEW ANNOUCEMENTS IN THE QUARTER:
The information contained in this section should be read in conjunction with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases available online in the Investors section of the company’s website at news releases .

Regulatory
Decisions

TECNIS SYNERGY and TECNIS SYNERGY TORIC II IOLS a Next Generation Treatment for Cataract Patients Received Regulatory Approval and Launched in the U.S. and Canada

(press release)

(press release)

RYBREVANT (amivantamab-vmjw) Receives U.S. FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

(press release)

PONVORY (ponesimod) receives European Commission approval for the Treatment of Adults with Relapsing Forms of Multiple Sclerosis with Active Disease Defined by Clinical or Imaging Features

(press release)

DARZALEX (daratumumab) Subcutaneous (SC) Formulation Becomes the First Approved Treatment for Newly Diagnosed Systemic Light Chain Amyloidosis in Europe and Gains an Additional Approval in Pre-Treated Multiple Myeloma

(press release)

DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) Receives U.S. FDA Approval for Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse 1

(press release)

Regulatory
Submissions

Janssen granted Breakthrough Therapy Designation from the U.S. FDA for Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma

(press release)

Janssen Submits Marketing Authorisation Application to the European Medicines Agency for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma

(press release)

Janssen Submits New Drug Application to U.S. FDA for XARELTO (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients

(press release)

Other

Johnson & Johnson Joins World Health Organization in Efforts to Prevent Spread of Ebola in West Africa

(press release)

Janssen Discontinues Collaboration and License Agreement with argenx for Cusatuzumab

(press release)

ETHICON expands Advanced Bipolar Energy Portfolio with Launch of ENSEAL X1 Curved Jaw Tissue Sealer

(press release)

Johnson & Johnson Announces Positive New Data for the Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response

(press release)

Johnson & Johnson Consumer Inc. Issues Voluntary Recall of Specific NEUTROGENA and AVEENO Aerosol Sunscreen Products Due to the Presence of Benzene 1

(press release)

1 Subsequent to the quarter

FULL-YEAR 2021 GUIDANCE:
Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson’s results computed in accordance with GAAP.

($ in Billions, except EPS)

April 2021

July 2021 (Base Business)

July 2021 (incl. COVID Vx)

Adjusted Operational Sales 1,2

Change vs. Prior Year

8.7% – 9.9%

9.5% – 10.5%

12.5% – 13.5%

Operational Sales 2

Change vs. Prior Year

$89.3B – $90.3B

8.2% – 9.4%

$90.0B – $90.8B

9.0% – 10.0%

$92.5B – $93.3B

12.0% – 13.0%

Estimated Reported Sales 3

Change vs. Prior Year

$90.6B – $91.6B

9.7% – 10.9%

$91.3B – $92.1B

10.5% – 11.5%

$93.8B – $94.6B

13.5% – 14.5%

Adjusted Operational EPS
(Diluted) 2,4

Change vs. Prior Year

$9.30 – $9.45

15.8% – 17.7%

$9.50 – $9.60

18.4% – 19.6%

Adjusted EPS (Diluted) 3,4

Change vs. Prior Year

$9.42 – $9.57

17.3% – 19.2%

$9.60 – $9.70

19.6% – 20.8%

1

Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures

2

Non-GAAP financial measure; excludes the impact of translational currency

3

Calculated using Euro Average Rate: April 2021 = $1.19 and July 2021 = $1.19 (Illustrative purposes only)

4

Non-GAAP financial measure; excludes intangible amortization expense and special items

Note: % may have been rounded

Other modeling considerations will be provided on the webcast .

WEBCAST INFORMATION:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time . A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website . A replay and podcast will be available approximately two hours after the live webcast in the Investors section of the company’s website at events-and-presentations .

ABOUT JOHNSON & JOHNSON:
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

NON-GAAP FINANCIAL MEASURES:
*Operational sales growth excluding the impact of translational currency, adjusted operational sales growth excluding the net impact of acquisitions and divestitures and translational currency, as well as adjusted net earnings, adjusted diluted earnings per share and adjusted operational diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investors section of the company’s website at quarterly-results .

Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly-results . These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in the Investors section of the company’s website at quarterly-results .

NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the Company’s ability to execute business continuity plans, as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 3, 2021 including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” in the Company’s most recently filed Quarterly Report on Form 10-Q and the Company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Johnson & Johnson and Subsidiaries

Supplementary Sales Data

(Unaudited; Dollars in Millions)

SECOND QUARTER

SIX MONTHS

Percent Change

Percent Change

2021

2020

Total

Operations

Currency

2021

2020

Total

Operations

Currency

Sales to customers by

segment of business

Consumer Health

U.S.

$   1,751

1,557

12.4

%

12.4

$   3,362

3,297

2.0

%

2.0

International

1,984

1,739

14.1

6.3

7.8

3,916

3,624

8.1

3.3

4.8

3,735

3,296

13.3

9.2

4.1

7,278

6,921

5.2

2.7

2.5

Pharmaceutical

U.S.

6,869

6,120

12.2

12.2

13,315

12,181

9.3

9.3

International

5,730

4,632

23.7

15.4

8.3

11,483

9,705

18.3

11.4

6.9

12,599

10,752

17.2

13.6

3.6

24,798

21,886

13.3

10.3

3.0

Medical Devices

U.S.

3,299

1,862

77.2

77.2

6,353

4,760

33.5

33.5

International

3,679

2,426

51.6

41.9

9.7

7,204

5,460

31.9

24.5

7.4

6,978

4,288

62.7

57.2

5.5

13,557

10,220

32.7

28.7

4.0

U.S.

11,919

9,539

24.9

24.9

23,030

20,238

13.8

13.8

International

11,393

8,797

29.5

20.9

8.6

22,603

18,789

20.3

13.7

6.6

Worldwide

$ 23,312

18,336

27.1

%

23.0

4.1

$ 45,633

39,027

16.9

%

13.7

3.2

Note:Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Johnson & Johnson and Subsidiaries

Supplementary Sales Data

(Unaudited; Dollars in Millions)

SECOND QUARTER

SIX MONTHS

Percent Change

Percent Change

2021

2020

Total

Operations

Currency

2021

2020

Total

Operations

Currency

Sales to customers by

geographic area

U.S.

$ 11,919

9,539

24.9

%

24.9

$ 23,030

20,238

13.8

%

13.8

Europe

5,668

4,063

39.5

28.6

10.9

11,082

8,890

24.7

15.6

9.1

Western Hemisphere excluding U.S.

1,367

1,133

20.6

12.7

7.9

2,791

2,635

5.9

5.4

0.5

Asia-Pacific, Africa

4,358

3,601

21.0

14.8

6.2

8,730

7,264

20.2

14.2

6.0

International

11,393

8,797

29.5

20.9

8.6

22,603

18,789

20.3

13.7

6.6

Worldwide

$ 23,312

18,336

27.1

%

23.0

4.1

$ 45,633

39,027

16.9

%

13.7

3.2

Note:Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)

SECOND QUARTER

2021

2020

Percent

Percent

Percent

Increase

Amount

to Sales

Amount

to Sales

(Decrease)

Sales to customers

$ 23,312

100.0

$ 18,336

100.0

27.1

Cost of products sold

7,587

32.5

6,579

35.9

15.3

Gross Profit

15,725

67.5

11,757

64.1

33.8

Selling, marketing and administrative expenses

6,073

26.1

4,993

27.2

21.6

Research and development expense

3,394

14.6

2,707

14.8

25.4

In-process research and development

0

0.0

6

0.0

Interest (income) expense, net

28

0.1

26

0.2

Other (income) expense, net

(488)

(2.1)

24

0.1

Restructuring

56

0.2

61

0.3

Earnings before provision for taxes on income

6,662

28.6

3,940

21.5

69.1

Provision for taxes on income

384

1.7

314

1.7

22.3

Net earnings

$   6,278

26.9

$   3,626

19.8

73.1

Net earnings per share (Diluted)

$     2.35

$     1.36

72.8

Average shares outstanding (Diluted)

2,671.6

2,665.5

Effective tax rate

5.8

%

8.0

%

Adjusted earnings before provision for taxes and net earnings (1)

Earnings before provision for taxes on income

$   7,776

33.4

$   5,337

29.1

45.7

Net earnings

$   6,625

28.4

$   4,446

24.2

49.0

Net earnings per share (Diluted)

$     2.48

$     1.67

48.5

Effective tax rate

14.8

%

16.7

%

(1) See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)

SIX MONTHS

2021

2020

Percent

Percent

Percent

Increase

Amount

to Sales

Amount

to Sales

(Decrease)

Sales to customers

$ 45,633

100.0

$ 39,027

100.0

16.9

Cost of products sold

14,650

32.1

13,641

35.0

7.4

Gross Profit

30,983

67.9

25,386

65.0

22.0

Selling, marketing and administrative expenses

11,505

25.2

10,196

26.1

12.8

Research and development expense

6,572

14.4

5,287

13.5

24.3

In-process research and development

0

0.0

6

0.0

Interest (income) expense, net

76

0.2

(16)

0.0

Other (income) expense, net

(1,370)

(3.0)

(655)

(1.7)

Restructuring

109

0.2

119

0.3

Earnings before provision for taxes on income

14,091

30.9

10,449

26.8

34.9

Provision for taxes on income

1,616

3.6

1,027

2.7

57.4

Net earnings

$ 12,475

27.3

$   9,422

24.1

32.4

Net earnings per share (Diluted)

$     4.67

$     3.53

32.3

Average shares outstanding (Diluted)

2,674.0

2,671.0

Effective tax rate

11.5

%

9.8

%

Adjusted earnings before provision for taxes and net earnings (1)

Earnings before provision for taxes on income

$ 16,067

35.2

$ 12,581

32.2

27.7

Net earnings

$ 13,549

29.7

$ 10,600

27.2

27.8

Net earnings per share (Diluted)

$     5.07

$     3.97

27.7

Effective tax rate

15.7

%

15.7

%

(1) See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and Subsidiaries

Reconciliation of Non-GAAP Financial Measures

Second Quarter

Six Months Ended

(Dollars in Millions Except Per Share Data)

2021

2020

2021

2020

Net Earnings, after tax- as reported

$6,278

$3,626

$12,475

$9,422

Pre-tax Adjustments

Intangible Asset Amortization expense

1,202

1,127

2,417

2,245

Litigation related

(23)

613

(23)

733

IPR&D

6

6

Restructuring related

108

115

212

233

Acquisition, integration and divestiture related ¹

14

29

(524)

(933)

Unrealized (gains)/losses on securities

(243)

(533)

(208)

(206)

Medical Device Regulation

56

37

102

51

Other

3

3

Tax Adjustments

Tax impact on special item adjustments 2

(135)

(253)

(248)

(520)

Tax legislation and other tax related

(632)

(324)

(654)

(434)

Adjusted Net Earnings, after tax

$6,625

$4,446

$13,549

$10,600

Average shares outstanding (Diluted)

2,671.6

2,665.5

2,674.0

2,671.0

Adjusted net earnings per share (Diluted)

$2.48

$1.67

$5.07

$3.97

Operational adjusted net earnings per share (Diluted)

$2.42

$4.91

Notes:

1

Acquisition, integration and divestiture related for the six months of 2021 primarily includes the gain on the divestiture of two Pharmaceutical brands outside of the U.S.  The six months of 2020 primarily includes a $983M Contingent Consideration reversal related to the timing of certain developmental milestones associated with the Auris Health acquisition.

2

The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

Johnson & Johnson and Subsidiaries

Reconciliation of Non-GAAP Financial Measure

Adjusted Operational Sales Growth

SECOND QUARTER 2021 ACTUAL vs. 2020 ACTUAL

Segments

Consumer Health

Pharmaceutical

Medical Devices

Total

WW As Reported

13.3%

17.2%

62.7%

27.1%

U.S.

12.4%

12.2%

77.2%

24.9%

International

14.1%

23.7%

51.6%

29.5%

WW Currency

4.1

3.6

5.5

4.1

U.S.

International

7.8

8.3

9.7

8.6

WW Operational

9.2%

13.6%

57.2%

23.0%

U.S.

12.4%

12.2%

77.2%

24.9%

International

6.3%

15.4%

41.9%

20.9%

General Surgery

Advanced Sterilization Products

1.2

0.2

U.S.

0.0

0.0

International

1.9

0.4

All Other Acquisitions and Divestitures

0.8

0.6

0.3

0.6

U.S.

0.6

(0.1)

0.7

0.1

International

1.1

1.5

0.0

1.0

WW Adjusted Operational

10.0%

14.1%

58.7%

23.8%

U.S.

13.0%

12.1%

77.9%

25.1%

International

7.4%

16.8%

43.8%

22.4%

Note: Percentages are based on actual, non-rounded figures and may not sum

Johnson & Johnson and Subsidiaries

Reconciliation of Non-GAAP Financial Measure

Adjusted Operational Sales Growth

SIX MONTHS 2021 ACTUAL vs. 2020 ACTUAL

Segments

Consumer Health

Pharmaceutical

Medical Devices

Total

WW As Reported

5.2%

13.3%

32.7%

16.9%

U.S.

2.0%

9.3%

33.5%

13.8%

International

8.1%

18.3%

31.9%

20.3%

WW Currency

2.5

3.0

4.0

3.2

U.S.

International

4.8

6.9

7.4

6.6

WW Operational

2.7%

10.3%

28.7%

13.7%

U.S.

2.0%

9.3%

33.5%

13.8%

International

3.3%

11.4%

24.5%

13.7%

General Surgery

Advanced Sterilization Products

0.8

0.2

U.S.

0.0

0.0

International

1.5

0.4

All Other Acquisitions and Divestitures

0.6

0.5

0.2

0.4

U.S.

0.5

(0.1)

0.5

0.1

International

0.7

1.2

0.0

0.8

WW Adjusted Operational

3.3%

10.7%

29.7%

14.4%

U.S.

2.5%

9.2%

33.9%

13.9%

International

4.0%

12.6%

26.0%

14.8%

Note : Percentages are based on actual, non-rounded figures and may not sum


REPORTED SALES vs. PRIOR PERIOD ($MM)


REPORTED SALES vs. PRIOR PERIOD ($MM)

SECOND QUARTER

SIX MONTHS

% Change

% Change

2021

2020

Reported

Operational (1)

Currency

2021

2020

Reported

Operational (1)

Currency

CONSUMER HEALTH SEGMENT (2)

OTC

US

$             675

627

7.7%

7.7%

$          1,274

1,316

-3.2%

-3.2%

Intl

633

522

21.2%

10.4%

10.8%

1,208

1,181

2.3%

-4.7%

7.0%

WW

1,307

1,149

13.8%

8.9%

4.9%

2,482

2,497

-0.6%

-3.9%

3.3%

SKIN HEALTH / BEAUTY

US

659

536

23.0%

23.0%

1,293

1,195

8.2%

8.2%

Intl

511

471

8.4%

1.4%

7.0%

1,040

929

12.0%

6.8%

5.2%

WW

1,170

1,007

16.2%

12.9%

3.3%

2,333

2,124

9.8%

7.6%

2.2%

ORAL CARE

US

165

170

-3.1%

-3.1%

328

346

-5.2%

-5.2%

Intl

260

227

14.6%

6.7%

7.9%

514

446

15.3%

10.2%

5.1%

WW

426

397

7.0%

2.5%

4.5%

843

792

6.3%

3.5%

2.8%

BABY CARE

US

97

96

0.8%

0.8%

193

188

2.4%

2.4%

Intl

290

260

11.5%

6.6%

4.9%

583

529

10.2%

9.0%

1.2%

WW

387

356

8.6%

5.0%

3.6%

776

717

8.1%

7.3%

0.8%

WOMEN’S HEALTH

US

3

3

-3.1%

-3.1%

6

7

-16.0%

-16.0%

Intl

227

199

14.2%

9.2%

5.0%

446

427

4.5%

3.1%

1.4%

WW

230

202

13.9%

9.0%

4.9%

452

434

4.2%

2.8%

1.4%

WOUND CARE / OTHER

US

153

126

20.9%

20.9%

268

245

9.3%

9.3%

Intl

64

59

7.3%

-2.8%

10.1%

125

111

12.1%

5.2%

6.9%

WW

216

185

16.6%

13.4%

3.2%

393

356

10.2%

8.0%

2.2%

TOTAL CONSUMER HEALTH

US

1,751

1,557

12.4%

12.4%

3,362

3,297

2.0%

2.0%

Intl

1,984

1,739

14.1%

6.3%

7.8%

3,916

3,624

8.1%

3.3%

4.8%

WW

$          3,735

3,296

13.3%

9.2%

4.1%

$          7,278

6,921

5.2%

2.7%

2.5%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD ($MM)

REPORTED SALES vs. PRIOR PERIOD ($MM)

SECOND QUARTER

SIX MONTHS

% Change

% Change

PHARMACEUTICAL SEGMENT (2,3)

2021

2020

Reported

Operational (1)

Currency

2021

2020

Reported

Operational (1)

Currency

IMMUNOLOGY

US

$          2,748

2,362

16.4%

16.4%

$          5,161

4,772

8.2%

8.2%

Intl

1,483

1,161

27.7%

18.2%

9.5%

2,984

2,389

24.9%

17.0%

7.9%

WW

4,231

3,523

20.1%

17.0%

3.1%

8,145

7,161

13.7%

11.1%

2.6%

REMICADE

US

540

593

-9.1%

-9.1%

1,029

1,218

-15.6%

-15.6%

US Exports (4)

93

133

-30.0%

-30.0%

150

243

-38.2%

-38.2%

Intl

255

208

22.4%

11.1%

11.3%

487

464

4.9%

-1.7%

6.6%

WW

888

935

-5.1%

-7.6%

2.5%

1,665

1,925

-13.5%

-15.1%

1.6%

SIMPONI / SIMPONI ARIA

US

290

256

12.8%

12.8%

545

528

3.2%

3.2%

Intl

294

289

1.7%

-3.8%

5.5%

601

547

9.8%

4.5%

5.3%

WW

584

546

6.9%

4.0%

2.9%

1,146

1,075

6.6%

3.8%

2.8%

STELARA

US

1,496

1,138

31.4%

31.4%

2,827

2,355

20.0%

20.0%

Intl

778

558

39.2%

28.6%

10.6%

1,595

1,161

37.3%

28.1%

9.2%

WW

2,274

1,697

34.0%

30.5%

3.5%

4,422

3,516

25.8%

22.7%

3.1%

TREMFYA

US

325

241

35.0%

35.0%

599

428

40.0%

40.0%

Intl

155

101

52.3%

41.1%

11.2%

298

210

41.8%

31.8%

10.0%

WW

479

342

40.2%

36.8%

3.4%

897

638

40.6%

37.3%

3.3%

OTHER IMMUNOLOGY

US

5

*

*

12

*

*

Intl

1

3

-61.3%

-67.9%

6.6%

3

6

-51.2%

-53.9%

2.7%

WW

7

3

*

*

*

15

6

*

*

*

INFECTIOUS DISEASES

US

444

416

6.8%

6.8%

956

852

12.2%

12.2%

Intl

585

463

26.3%

18.2%

8.1%

1,079

946

14.1%

7.8%

6.3%

WW

1,028

878

17.1%

12.8%

4.3%

2,035

1,798

13.2%

9.9%

3.3%

COVID-19 VACCINE

US

51

*

*

151

*

*

Intl

113

*

*

113

*

*

WW

164

*

*

264

*

*

EDURANT / rilpivirine

US

9

10

-9.3%

-9.3%

19

22

-10.9%

-10.9%

Intl

253

246

2.8%

-4.0%

6.8%

486

458

6.0%

-1.7%

7.7%

WW

262

256

2.3%

-4.2%

6.5%

505

480

5.2%

-2.1%

7.3%

PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA

US

368

379

-3.2%

-3.2%

748

775

-3.5%

-3.5%

Intl

137

130

5.5%

-5.9%

11.4%

303

314

-3.5%

-8.5%

5.0%

WW

505

510

-1.0%

-3.9%

2.9%

1,051

1,089

-3.5%

-5.0%

1.5%

OTHER INFECTIOUS DISEASES

US

16

25

-36.2%

-36.2%

37

54

-31.3%

-31.3%

Intl

81

87

-6.2%

-13.4%

7.2%

177

174

1.8%

-3.0%

4.8%

WW

98

113

-13.0%

-18.5%

5.5%

215

229

-6.1%

-9.7%

3.6%


REPORTED SALES vs. PRIOR PERIOD ($MM)


REPORTED SALES vs. PRIOR PERIOD ($MM)

SECOND QUARTER


SIX MONTHS

% Change

% Change

2021

2020

Reported

Operational (1)

Currency

2021

2020

Reported

Operational (1)

Currency

NEUROSCIENCE

US

842

778

8.0%

8.0%

1,613

1,526

5.6%

5.6%

Intl

967

809

19.6%

13.1%

6.5%

1,916

1,719

11.5%

6.3%

5.2%

WW

1,808

1,587

13.9%

10.6%

3.3%

3,529

3,245

8.7%

6.0%

2.7%

CONCERTA / Methylphenidate

US

35

55

-36.0%

-36.0%

82

107

-23.1%

-23.1%

Intl

127

94

33.7%

25.6%

8.1%

250

212

17.5%

11.1%

6.4%

WW

161

149

8.1%

3.0%

5.1%

332

320

3.9%

-0.3%

4.2%

INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA

US

645

576

11.9%

11.9%

1,234

1,120

10.2%

10.2%

Intl

380

303

25.1%

15.9%

9.2%

756

642

17.7%

9.9%

7.8%

WW

1,024

879

16.4%

13.3%

3.1%

1,989

1,762

12.9%

10.1%

2.8%

RISPERDAL CONSTA

US

72

74

-3.0%

-3.0%

139

150

-7.5%

-7.5%

Intl

84

79

6.4%

0.2%

6.2%

173

173

0.4%

-4.6%

5.0%

WW

155

153

1.9%

-1.3%

3.2%

312

323

-3.3%

-6.0%

2.7%

OTHER NEUROSCIENCE

US

91

75

20.9%

20.9%

158

150

5.6%

5.6%

Intl

377

331

13.8%

10.0%

3.8%

738

691

6.7%

4.3%

2.4%

WW

468

406

15.1%

12.0%

3.1%

896

841

6.5%

4.5%

2.0%

ONCOLOGY

US

1,462

1,181

23.7%

23.7%

2,839

2,356

20.5%

20.5%

Intl

2,073

1,609

28.8%

19.8%

9.0%

4,266

3,448

23.7%

16.2%

7.5%

WW

3,535

2,791

26.7%

21.5%

5.2%

7,105

5,804

22.4%

17.9%

4.5%

DARZALEX

US

770

492

56.7%

56.7%

1,461

955

53.1%

53.1%

Intl

663

409

62.1%

50.3%

11.8%

1,337

883

51.4%

42.3%

9.1%

WW

1,433

901

59.2%

53.8%

5.4%

2,798

1,838

52.2%

47.9%

4.3%

ERLEADA

US

193

136

41.5%

41.5%

364

255

42.7%

42.7%

Intl

109

33

*

*

*

199

57

*

*

*

WW

302

170

77.6%

73.7%

3.9%

563

313

80.0%

76.4%

3.6%

IMBRUVICA

US

454

447

1.7%

1.7%

898

879

2.2%

2.2%

Intl

662

502

31.9%

22.1%

9.8%

1,342

1,101

21.9%

14.2%

7.7%

WW

1,116

949

17.7%

12.5%

5.2%

2,241

1,980

13.2%

8.9%

4.3%

ZYTIGA / abiraterone acetate

US

21

87

-75.3%

-75.3%

71

226

-68.5%

-68.5%

Intl

542

480

12.8%

5.4%

7.4%

1,130

1,032

9.5%

2.5%

7.0%

WW

563

568

-0.8%

-7.1%

6.3%

1,201

1,258

-4.5%

-10.3%

5.8%

OTHER ONCOLOGY

US

23

20

18.8%

18.8%

44

42

6.3%

6.3%

Intl

97

185

-47.2%

-49.6%

2.4%

258

375

-31.0%

-34.3%

3.3%

WW

120

204

-40.9%

-43.0%

2.1%

302

416

-27.3%

-30.2%

2.9%

REPORTED SALES vs. PRIOR PERIOD ($MM)

REPORTED SALES vs. PRIOR PERIOD ($MM)

SECOND QUARTER

SIX MONTHS

% Change

% Change

2021

2020

Reported

Operational (1)

Currency

2021

2020

Reported

Operational (1)

Currency

PULMONARY HYPERTENSION

US

595

545

9.0%

9.0%

1,168

1,031

13.2%

13.2%

Intl

275

243

13.5%

7.9%

5.6%

563

503

12.1%

6.7%

5.4%

WW

870

789

10.4%

8.7%

1.7%

1,731

1,534

12.9%

11.1%

1.8%

OPSUMIT

US

290

256

13.6%

13.6%

562

485

15.9%

15.9%

Intl

172

150

14.9%

9.0%

5.9%

351

310

13.1%

7.6%

5.5%

WW

463

406

14.1%

11.9%

2.2%

913

795

14.8%

12.7%

2.1%

UPTRAVI

US

268

254

6.0%

6.0%

527

466

13.3%

13.3%

Intl

45

28

54.9%

42.9%

12.0%

91

66

36.8%

27.4%

9.4%

WW

313

282

11.0%

9.8%

1.2%

618

532

16.2%

15.0%

1.2%

OTHER PULMONARY HYPERTENSION

US

36

37

-2.4%

-2.4%

78

81

-3.0%

-3.0%

Intl

59

64

-8.2%

-10.3%

2.1%

122

126

-3.5%

-6.3%

2.8%

WW

95

101

-6.1%

-7.5%

1.4%

200

207

-3.3%

-5.0%

1.7%

CARDIOVASCULAR / METABOLISM / OTHER

US

780

837

-6.9%

-6.9%

1,579

1,643

-3.9%

-3.9%

Intl

346

347

-0.3%

-8.4%

8.1%

674

701

-3.8%

-9.9%

6.1%

WW

1,126

1,184

-5.0%

-7.3%

2.3%

2,253

2,344

-3.9%

-5.7%

1.8%

XARELTO

US

569

559

1.8%

1.8%

1,158

1,086

6.6%

6.6%

Intl

WW

569

559

1.8%

1.8%

1,158

1,086

6.6%

6.6%

INVOKANA / INVOKAMET

US

96

132

-27.0%

-27.0%

183

249

-26.6%

-26.6%

Intl

64

47

33.8%

22.1%

11.7%

127

105

20.3%

12.2%

8.1%

WW

160

179

-10.9%

-14.0%

3.1%

310

354

-12.6%

-15.0%

2.4%

PROCRIT / EPREX

US

59

70

-16.3%

-16.3%

121

146

-17.3%

-17.3%

Intl

69

66

3.7%

-4.5%

8.2%

133

145

-8.2%

-14.1%

5.9%

WW

127

136

-6.6%

-10.6%

4.0%

254

291

-12.8%

-15.7%

2.9%

OTHER

US

57

78

-26.7%

-26.7%

117

163

-27.8%

-27.8%

Intl

214

234

-8.4%

-15.7%

7.3%

415

451

-8.1%

-13.7%

5.6%

WW

271

312

-13.0%

-18.4%

5.4%

532

614

-13.3%

-17.4%

4.1%

TOTAL PHARMACEUTICAL

US

6,869

6,120

12.2%

12.2%

13,315

12,181

9.3%

9.3%

Intl

5,730

4,632

23.7%

15.4%

8.3%

11,483

9,705

18.3%

11.4%

6.9%

WW

$        12,599

10,752

17.2%

13.6%

3.6%

$        24,798

21,886

13.3%

10.3%

3.0%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD ($MM)

REPORTED SALES vs. PRIOR PERIOD ($MM)

SECOND QUARTER

SIX MONTHS

% Change

% Change

MEDICAL DEVICES SEGMENT (2)

2021

2020

Reported

Operational (1)

Currency

2021

2020

Reported

Operational (1)

Currency

INTERVENTIONAL SOLUTIONS

US

$             475

255

86.5%

86.5%

909

620

46.7%

46.7%

Intl

572

335

70.5%

59.8%

10.7%

1,086

697

55.7%

46.4%

9.3%

WW

1,046

590

77.4%

71.3%

6.1%

1,995

1,317

51.5%

46.5%

5.0%

ORTHOPAEDICS

US

1,323

869

52.3%

52.3%

2,572

2,119

21.4%

21.4%

Intl

904

583

55.1%

43.2%

11.9%

1,768

1,371

29.0%

20.2%

8.8%

WW

2,227

1,451

53.4%

48.6%

4.8%

4,340

3,489

24.4%

20.9%

3.5%

HIPS

US

234

137

70.5%

70.5%

444

343

29.6%

29.6%

Intl

159

88

78.6%

64.3%

14.3%

305

220

38.3%

28.6%

9.7%

WW

392

226

73.7%

68.1%

5.6%

749

563

33.0%

29.2%

3.8%

KNEES

US

210

108

94.3%

94.3%

395

322

22.7%

22.7%

Intl

140

66

*

95.1%

16.8%

272

196

39.2%

29.5%

9.7%

WW

350

174

*

94.6%

6.4%

667

517

28.9%

25.2%

3.7%

TRAUMA

US

447

354

26.0%

26.0%

897

761

17.8%

17.8%

Intl

263

198

32.7%

22.7%

10.0%

545

445

22.5%

14.4%

8.1%

WW

710

553

28.4%

24.8%

3.6%

1,443

1,207

19.6%

16.5%

3.1%

SPINE, SPORTS & OTHER

US

433

270

60.6%

60.6%

836

693

20.7%

20.7%

Intl

343

230

49.0%

37.9%

11.1%

646

510

26.7%

18.0%

8.7%

WW

776

499

55.3%

50.2%

5.1%

1,482

1,202

23.2%

19.6%

3.6%

REPORTED SALES vs. PRIOR PERIOD ($MM)

REPORTED SALES vs. PRIOR PERIOD ($MM)

SECOND QUARTER

SIX MONTHS

% Change

% Change

2021

2020

Reported

Operational (1)

Currency

2021

2020

Reported

Operational (1)

Currency

SURGERY

US

1,035

490

*

*

1,933

1,334

44.9%

44.9%

Intl

1,487

1,060

40.2%

30.6%

9.6%

2,961

2,317

27.8%

20.4%

7.4%

WW

2,522

1,551

62.6%

56.0%

6.6%

4,894

3,651

34.0%

29.3%

4.7%

ADVANCED

US

459

277

65.4%

65.4%

864

658

31.3%

31.3%

Intl

708

498

42.2%

32.5%

9.7%

1,421

1,065

33.4%

25.6%

7.8%

WW

1,168

775

50.5%

44.3%

6.2%

2,286

1,723

32.6%

27.8%

4.8%

GENERAL

US

576

213

*

*

1,069

676

58.1%

58.1%

Intl

779

562

38.5%

28.9%

9.6%

1,540

1,252

23.0%

15.9%

7.1%

WW

1,354

775

74.7%

67.8%

6.9%

2,608

1,928

35.3%

30.7%

4.6%

VISION

US

467

248

88.3%

88.3%

939

687

36.6%

36.6%

Intl

716

447

60.0%

53.7%

6.3%

1,389

1,075

29.2%

24.6%

4.6%

WW

1,183

695

70.1%

66.0%

4.1%

2,328

1,762

32.1%

29.3%

2.8%

CONTACT LENSES / OTHER

US

352

203

73.3%

73.3%

723

549

31.6%

31.6%

Intl

517

352

47.0%

41.9%

5.1%

1,003

819

22.5%

18.5%

4.0%

WW

868

554

56.7%

53.4%

3.3%

1,725

1,368

26.1%

23.7%

2.4%

SURGICAL

US

115

45

*

*

216

138

56.3%

56.3%

Intl

199

96

*

97.1%

10.6%

386

256

50.9%

44.4%

6.5%

WW

314

141

*

*

*

602

394

52.8%

48.6%

4.2%

TOTAL MEDICAL DEVICES

US

3,299

1,862

77.2%

77.2%

6,353

4,760

33.5%

33.5%

Intl

3,679

2,426

51.6%

41.9%

9.7%

7,204

5,460

31.9%

24.5%

7.4%

WW

$          6,978

4,288

62.7%

57.2%

5.5%

$        13,557

10,220

32.7%

28.7%

4.0%

Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely.

* Percentage greater than 100% or not meaningful

(1) Operational growth excludes the effect of translational currency

(2) Unaudited

(3) Certain prior year amounts have been reclassified to conform to current year product disclosures

(4) Reported as U.S. sales

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/johnson–johnson-reports-q2-2021-results-301338422.html

SOURCE Johnson & Johnson

News Provided by PR Newswire via QuoteMedia

  Life Science and Healthcare Investing report cover

Life Science and Healthcare Investing in 2021

 
The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2021 life science outlook report!
 

Tags

Leave a Reply